Rizatriptan Benzoate
Product Images NDC 45865-825

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 45865-825). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (825 12)

Pdp (825 12)
Description: Rizatriptan Benzoate is a medication available in tablet form, generic for Maxalt, and manufactured by Breckenridge Pharmaceutical, Inc. It contains 10mg of Rizatriptan Benzoate per oblong, light pink tablet. The medication may cause dizziness or drowsiness, so one must avoid taking alcohol. The dose should be taken as directed by the physician. The other information includes NDC codes, lot number, and expiration date. Note: The text contains some readable non-English characters.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
This text appears to be a section of a report or study discussing the efficacy of tizatriptan in treating headaches compared to a placebo. It includes a graph (KaplanMeler plot) showing the probability of headache response over time, based on data from four trials. The text mentions that patients who did not achieve headache response after two hours were censored.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
This is a description of a Kaplan-Meier plot based on data obtained in 4 outpatient clinical trials. The plot shows the treatment efficacy of a medication called "Eatmsea ooty" for relieving headaches. The study included patients who had a headache response at 2 hours and those who had no response to the medication. Patients using additional treatments were censored at 24 hours. Remedication was not allowed within 2 hours post-dose.*
FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.